Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/28/23 is in compliance with the provisions of 37 CFR 1.97(b). Accordingly, the IDS is being considered by the Examiner. Allowable Subject Matter Claim s 21-23 are allowed. Claim s 4, 7, objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis ( i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale , or otherwise available to the public before the effective filing date of the claimed invention. Claims 1- 3 , 6, 8-13, 16-17 , 19-20 are rejected under 35 U.S.C. 102 (a)(1) as being anticipated by Dewollfson et al. (US 2013/0144260) (“ Dewollfson ”) . Dewollfson discloses: (Figs. 4-8) (claim 1) A medicament dispenser comprising: a body 2c,12 comprising an inlet 15 configured to interface with a syringe and an outlet 5b configured to interface with a needle; a dosing chamber 14 within said body comprising a dosing chamber inlet fluidly connected to the inlet of the body and a dosing chamber outlet fluidly connected to the outlet of the body, the dosing chamber being configured to contain a fixed volume of medicament when full; and a piston 6b configured to be movable within the dosing chamber to deliver the fixed volume of medicament out of the outlet of the body. Claim 2: the dosing chamber inlet is fluidly connected to the inlet of the body by an inlet passage and the dosing chamber outlet is fluidly connected to the outlet of the body by an outlet passage. (Fig. 6) Claim 3: a dosing chamber axis of the dosing chamber is angled (90 degrees) with respect to an inlet axis of the inlet of the body (Fig. 6) Claim 6: when the medicament dispenser is orientated with the outlet of the body pointing vertically upwards, a level of the dosing chamber outlet is above a level of the dosing chamber inlet. (rotate Fig. 6) Claim 8: the inlet and the outlet are laterally offset from one another; and optionally are laterally offset and parallel to one another. (Fig. 6) Claim 9: the dosing chamber outlet is located in a terminal end face of the dosing chamber. (Fig. 6) Claim 10: the dosing chamber outlet is located at or adjacent a peripheral edge of a terminal end face of the dosing chamber. (Fig. 6) Claim 11: the terminal end face smoothly transitions to the outlet passage (Fig. 6) Claim 12: the piston 6b is configured to move within the dosing chamber from a pre-activation position to an activated position to deliver the fixed volume of medicament from the dosing chamber through the outlet. (Fig. 7) Claim 13: in the pre-activation position an end face of the piston is located immediately adjacent the dosage chamber inlet (Fig. 6) Claim 16: a plunger 13 that is operatively connected to the piston 6b ; and wherein the plunger extends outside the body of the medicament dispenser. (Fig. 6) Claim 17: a plunger lock for preventing accidental activation of the plunger [0076] Claim 19: a syringe 16 containing medicament, the syringe being connectable to the inlet of the body. (Fig. 5) Claim 20: the syringe comprises a medicament-containing chamber having an internal diameter that is larger than an internal diameter of the dosing chamber of the medicament dispenser. (Fig. 5) Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis ( i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 15 is rejected under 35 U.S.C. 103 as being unpatentable over Dewoolfson . Dewoolfson discloses the invention as substantially claimed but does not directly disclose wherein the dosing chamber has an internal diameter of less than or equal to 4.0 mm; optionally less or equal to 3.5 mm; optionally less or equal to 3.0 mm. It would be obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to use these diameters because Dewoolfson does teach that the volume of the hollow cavity (dosing chamber 14) may be selected appropriately for the area of the body being treated and the type of agent injected [0096]. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT DEANNA K HALL whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)272-2819 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT M-F 8:30am- 4:30pm EST . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Kevin Sirmons can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-272-4965 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEANNA K HALL/ Primary Examiner, Art Unit 3783